All In Biotech

Drug Trial Radar · NCT06486142

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Sep 21, 2022

Primary completion

Sep 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Region SkaneAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Swedish Lung Cancer Study Group
First posted
Jul 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment. Life quality, adverse effects and tumor response will be evaluated and analyses of obtained blood and tumor samples will be performed to identify molecular profiles and biomarkers that can be used for treatment decisions.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • Afatinib/DacomitinibDrug

    Second-generation EGFR-inhibitors

  • OsimertinibDrug

    Third-generation EGFR-inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Maximum 6 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Skåne university hospital

    Lund, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.